+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032- Product Image
Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032- Product Image
New

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 198 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124752
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hepatitis C Antiviral Drugs Market is advancing into a new phase where practical delivery, broad accessibility, and consistent patient outcomes shape the landscape, requiring agile strategies from industry leaders to sustain growth.

Market Snapshot: Hepatitis C Antiviral Drugs Market

The antiviral drugs market for hepatitis C grew from USD 15.67 billion in 2025 to USD 16.87 billion in 2026 and is projected to reach USD 27.89 billion by 2032, with a CAGR of 8.57%. Expansion is increasingly influenced by the ability of companies to execute reliably, integrate rapid diagnostic-to-treatment pathways, and navigate evolving supply chain requirements. Beyond medical innovation, the market is now defined by operational excellence and the capability to deliver effective therapies in a variety of care settings. Shifting patient demographics and a complex regulatory environment further underscore the need for resilient, adaptive commercial strategies as competition intensifies.

Scope & Segmentation

  • Therapy Classes: Direct-acting antivirals, such as NS5A inhibitors, NS5B polymerase inhibitors, and protease inhibitors, serve as the primary choice in clinical hepatitis C treatment regimens, directly impacting therapy selection and patient suitability.
  • Delivery Models: Test-and-treat strategies, streamlined prescribing approaches, and the ability to initiate therapy in both specialist and community healthcare settings are gaining emphasis to expedite patient access.
  • Route of Administration: Oral therapies predominate, with increasing focus on monitoring adherence and ensuring availability in decentralized locations to expand reach.
  • Distribution Channels: Hospital pharmacies, retail pharmacy networks, and online channels each play a distinct role in maintaining medication access and continuous therapy for patients.
  • End Users: Hospitals, specialty clinics, ambulatory surgical centers, and community health centers exhibit diverse models for treatment initiation and ongoing patient management.
  • Regional Coverage: The Americas, Europe, Middle East & Africa, and Asia-Pacific face unique policy, access, and health infrastructure challenges shaping strategic priorities.
  • Key Technologies: Digital adherence solutions, point-of-care rapid diagnostics, integrated real-world data analytics, and resilient supply chain management tools underpin competitive advantage.

Key Takeaways for Senior Decision-Makers

  • Growth increasingly relies on expanding treatment access for underserved and high-risk populations, demonstrating the need for scalable, adaptable models such as test-and-treat protocols.
  • Therapy selection focuses not only on efficacy but on operational factors such as drug-drug interaction profiles, streamlined prescribing, and patient adherence for those with complex comorbidities.
  • Long-term value is built by monitoring outcomes beyond the cure, specifically verifying sustained virologic response and proactively managing reinfection risks to strengthen program credibility.
  • Robust supply chain management and contingency planning are emerging as essential differentiators in a tightening procurement environment, mitigating risks and supporting contract stability.
  • Regional performance hinges on the alignment of treatment strategies, optimized distribution channels, and effective policy implementation, not solely on product innovation.
  • Ecosystem support—including tailored educational resources, adherence enhancement tools, and strong channel partnerships—is critical to securing program success and commercial sustainability.

Tariff Impact: 2025 Policy Scenarios and Supply Chain Implications

With anticipated U.S. tariffs in 2025, the hepatitis C antiviral drugs sector may face increased complexity across supply chains and manufacturing. Tariff measures could influence sourcing of active ingredients, procurement of packaging, and logistics, adding pressure to cost and margin structures. Strategic responses may include negotiating new contracts, building safety stocks, and localizing packaging processes. For organizations managing mature portfolios, decision-makers will need to balance cost reconfiguration with resilience and continued market access, making tariff risk management pivotal for procurement and portfolio planning.

Methodology & Data Sources

This research leverages a hybrid methodology that integrates direct interviews with key value chain stakeholders along with a comprehensive review of regulatory, clinical, and commercial datasets. The approach ensures that the findings reflect triangulated insights into market segmentation, operational challenges, and policy impacts across major global regions.

Hepatitis C Antiviral Drugs: Why This Report Matters

  • Empowers decision-makers to refine operational tactics, speeding the transition from diagnosis to treatment while enhancing patient retention rates.
  • Provides actionable perspectives on how tariff policies and regional trends influence procurement efficiency, supply security, and broader commercial approaches.
  • Enables data-driven strategies for allocating resources, aligning distribution channels, and scaling in markets with the greatest unmet needs.

Conclusion

The hepatitis C antiviral drugs market is characterized by the need for scalable, high-impact delivery models and robust outcome measurement. Continued success will depend on innovative access solutions, stable supply frameworks, and coordinated alignment within evolving care systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Antiviral Drugs for the Treatment of Hepatitis C Market, by Product Type
8.1. Direct-Acting Antivirals
8.2. Interferons
8.3. Ribavirin
9. Antiviral Drugs for the Treatment of Hepatitis C Market, by Mechanism Of Action
9.1. NS3/4A Protease Inhibitors
9.2. NS5A Inhibitors
9.3. NS5B Polymerase Inhibitors
9.3.1. Non-Nucleoside Inhibitors
9.3.2. Nucleoside Inhibitors
10. Antiviral Drugs for the Treatment of Hepatitis C Market, by Therapy Type
10.1. Combination Therapy
10.2. Monotherapy
11. Antiviral Drugs for the Treatment of Hepatitis C Market, by Formulation
11.1. Injectable
11.2. Oral
12. Antiviral Drugs for the Treatment of Hepatitis C Market, by Genotype
12.1. Genotype 1
12.2. Genotype 2
12.3. Genotype 3
12.4. Genotype 4
12.5. Genotype 5
12.6. Genotype 6
13. Antiviral Drugs for the Treatment of Hepatitis C Market, by Distribution Channel
13.1. Hospital Pharmacies
13.2. Online Pharmacies
13.3. Retail Pharmacies
14. Antiviral Drugs for the Treatment of Hepatitis C Market, by End User
14.1. Clinics
14.2. Homecare
14.3. Hospitals
15. Antiviral Drugs for the Treatment of Hepatitis C Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Antiviral Drugs for the Treatment of Hepatitis C Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Antiviral Drugs for the Treatment of Hepatitis C Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Antiviral Drugs for the Treatment of Hepatitis C Market
19. China Antiviral Drugs for the Treatment of Hepatitis C Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. AbbVie Inc.
20.6. AstraZeneca plc
20.7. Aurobindo Pharma Limited
20.8. Boehringer Ingelheim International GmbH
20.9. Bristol-Myers Squibb Company
20.10. Cipla Limited
20.11. Dr. Reddy’s Laboratories Ltd.
20.12. F. Hoffmann-La Roche Ltd
20.13. Gilead Sciences, Inc.
20.14. GlaxoSmithKline plc
20.15. Hetero Drugs Limited
20.16. Johnson & Johnson
20.17. Merck & Co., Inc.
20.18. Natco Pharma Limited
20.19. Novartis AG
20.20. Pfizer Inc.
20.21. Sun Pharmaceutical Industries Ltd.
20.22. Teva Pharmaceutical Industries Ltd.
20.23. Vertex Pharmaceuticals Incorporated
20.24. Viatris Inc.
20.25. Zydus Cadila
List of Figures
FIGURE 1. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 122. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 123. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 139. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 140. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 141. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 142. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 143. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 144. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 158. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 159. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 161. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 162. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 163. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 167. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 168. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 169. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 170. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 171. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 172. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 185. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 186. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 189. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 190. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 194. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 195. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 196. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 197. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 198. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 199. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 203. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 204. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 206. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 207. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 208. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 222. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 223. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 224. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 225. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 226. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
TABLE 227. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antiviral Drugs for the Treatment of Hepatitis C market report include:
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zydus Cadila

Table Information

Report AttributeDetails
No. of Pages198
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.87 Billion
Forecasted Market Value ( USD ) by 2032 $ 27.89 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Hepatitis Therapeutics Market - Global Forecast 2026-2032 - Product Image

Hepatitis Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Direct Acting Antivirals Market - Global Forecast 2026-2032 - Product Image

Direct Acting Antivirals Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Hepatitis C Market Report 2025 - Product Image

Hepatitis C Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hepatitis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Hepatitis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.